May 21, 2020

Oxurion NV to Present at 2019 Biotech Showcase[TM] Conferenc

Bizclik Editor
3 min

LEUVEN, Belgium, December 19, 2018 /PRNewswire/ --

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview at the 2019 Biotech Showcase [TM] conference at 3:30 p.m. PST on Tuesday, Jan. 8, 2019 at the Hilton San Francisco Union Square.

Additionally, Dr. De Haes will participate in a CEO power breakfast roundtable as a panellist at 7 a.m. PST on Wednesday, Jan. 9, 2019 at the Sir Francis Drake Hotel in San Francisco. The panel will feature life sciences executives examining topics including drug innovation and strategic partnering moderated by FierceBiotech editor, Amirah Al Idrus. Please fill out the contact form to RSVP for the event.

Furthermore, Oxurion's management team will also hold one-on-one meetings with institutional investors and analysts Jan. 7-9 in San Francisco. Institutional investors and analysts can register and request meetings through the online system .
About Oxurion  

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company focused on transforming treatments to preserve vision in patients with diseases affecting the back of the eye. The company is currently developing a competitive pipeline of disease-modifying drug candidates for diabetic eye disease, a leading cause of blindness of people of working age worldwide.

Oxurion's most advanced drug candidate is THR-317, a PlGF inhibitor for the treatment of diabetic macular edema (DME), which is currently in a Phase 2 study in combination with Lucentis®. THR-317 is also being evaluated in a Phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal disease that affects the macula and can lead to vision loss.

Oxurion has two further pipeline candidates, THR-149, a plasma kallikrein inhibitor being developed for the treatment of DME; and THR-687, a pan-RGD integrin antagonist in development for the treatment of diabetic retinopathy and DME. Both THR-149 and THR-687 are in Phase 1 clinical studies.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at

Important information about forward-looking statements 

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.  No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. 

For further information please contact: 

Oxurion NV
Wouter Piepers,
Global Head of Corp Coms & Investor relations
+32-16-75-13-10 / +32-478-33-56-32
[email protected]

EU - Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi
Tel: +44-20-7638-9571
[email protected]

US - LifeSci Public Relations
Alison Chen
[email protected]


Share article

Subscribe to our Newsletter
Receive the latest updates and news
Exclusive preview